Madrigal pharmaceuticals, inc. (MDGL)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net loss

-105,003

-83,948

-67,683

-54,766

-41,527

-32,811

-29,781

-29,632

-31,519

-31,154

-30,458

-36,144

-30,674

-26,388

-29,175

-32,754

-49,677

-68,671

-78,487

-80,825

-83,311

-86,161

-89,971

-92,520

-93,021

-90,192

-84,153

-76,634

-68,467

-62,790

-55,410

-53,148

-51,030

-47,380

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
PIK interest expense on convertible promissory notes payable - related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

1,207

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

21,583

22,759

23,846

23,872

18,344

13,489

9,317

5,370

3,819

3,254

0

0

0

-

-

-

-

4,300

5,487

5,885

6,555

7,431

7,205

7,322

7,400

6,030

5,453

4,571

3,711

3,322

3,207

3,273

3,354

3,354

0

0

0

Depreciation and amortization expense

209

112

109

105

101

96

0

0

0

-

-

-

-

-

-

-

-

662

672

673

674

673

647

628

584

516

488

510

608

738

914

1,094

1,255

1,464

0

0

0

Changes in operating assets and liabilities:
Accounts receivable - related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-7

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-116

0

0

0

Prepaid expenses and other current assets

381

-332

946

1,901

400

998

69

-496

-272

-502

-1,298

-1,951

-1,913

-1,290

-1,056

-354

-63

-455

-936

-51

-238

-102

560

-366

-863

-21

555

798

867

225

-559

7

84

130

0

0

0

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-305

-105

-80

180

-111

891

887

896

951

-33

-39

-38

-173

-64

6

102

265

0

0

0

Accounts payable

-3,261

-1,309

-258

-142

2,956

558

-619

-947

-1,610

917

240

-134

1,522

-128

145

-1,190

-2,070

-1,840

-3,018

-2,208

-2,072

-3,450

-1,251

5

90

928

2,003

1,753

2,679

2,194

768

1,469

1,349

1,542

0

0

0

Accrued expense

17,594

16,783

8,770

6,716

904

-2,168

-1,512

-303

1,748

4,087

4,368

-1,582

-3,221

-2,281

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest, net of interest received on maturity of investments

3,607

3,647

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

6

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-65,652

-41,624

-35,607

-29,521

-23,341

-25,507

-25,187

-24,900

-27,190

-22,317

-21,652

-25,944

-20,941

-17,608

-31,665

-38,024

-53,107

-71,444

-71,322

-74,286

-77,430

-78,925

-78,400

-76,422

-75,467

-77,411

-71,244

-67,919

-61,095

-54,135

-52,098

-50,656

-49,715

-47,300

0

0

0

Cash flows from investing activities:
Accrued contract research costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,454

2,930

1,741

23

1,910

5,924

7,076

7,587

5,646

4,633

2,135

894

1,920

709

905

754

330

0

0

0

Other accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,201

53

317

643

459

497

1,588

1,926

591

854

505

309

533

394

210

378

400

0

0

0

Deferred collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,731

0

0

0

Purchases of marketable securities

504,113

619,303

496,496

628,605

666,002

614,358

560,236

290,967

170,285

70,211

0

0

0

-

-

-

-

117,135

117,811

155,053

118,980

93,845

111,478

70,582

62,409

114,151

75,329

88,560

82,499

50,033

49,619

33,820

59,016

50,726

0

0

0

Sales and maturities of marketable securities

589,216

650,182

582,744

464,573

384,620

234,304

161,271

97,131

56,838

48,330

0

0

0

-

-

-

-

137,193

125,898

103,962

102,384

85,152

88,588

91,746

91,085

90,267

73,117

71,209

49,895

40,595

53,946

51,748

59,053

60,745

0

0

0

Purchases of property and equipment, net of disposals

445

172

46

61

62

22

14

1

124

125

0

0

0

-

-

-

-

-

-

-

-

144

167

146

516

769

771

964

634

505

803

857

827

690

0

0

0

Net cash provided by (used in) investing activities

84,658

30,707

86,202

-164,093

-281,444

-380,076

-398,979

-193,837

-113,571

-22,006

0

0

0

-

-

-

-

20,000

7,988

-51,214

-16,717

-8,837

-23,057

21,018

28,160

-24,653

-2,983

-18,315

-33,238

-9,943

3,524

17,071

-790

9,329

0

0

0

Cash flows from financing activities:
Proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

53,545

0

0

0

-

-

-

-

Proceeds from the exercise of common stock options

-

-

-

-

-

-

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net of transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

89,796

127,448

99,337

47,808

38,735

38,370

38,517

39,089

66,248

0

0

0

-

-

-

-

Proceeds from convertible notes - related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

8,500

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, excluding to related parties, and exercise of common stock options, net of transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from term loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,500

0

0

0

-

-

-

-

2,000

0

0

0

Payment of term loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,214

9,207

9,200

9,261

9,450

7,385

5,306

3,135

2,617

4,349

6,093

6,055

4,234

0

0

0

-

-

-

-

Payment of capital lease obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

42

42

41

41

42

34

28

21

13

13

13

12

12

20

30

117

201

0

0

0

Net cash provided by financing activities

152

235

845

1,261

314,153

314,335

449,252

448,801

170,671

173,805

44,232

45,857

17,103

14,454

6,184

10,075

43,447

40,386

40,393

60,692

75,368

85,296

144,458

118,432

64,379

69,042

70,262

94,424

94,745

115,515

57,373

33,287

67,683

36,736

0

0

0

Net increase (decrease) in cash and cash equivalents

19,158

-10,682

51,440

-192,353

9,368

-91,248

25,086

230,064

29,910

129,482

4,567

30,701

7,597

18,839

-2,484

6,753

2,023

-11,058

-22,941

-64,808

-18,779

-2,466

43,001

63,028

17,072

-33,022

-3,965

8,190

412

51,437

8,799

-298

17,178

-1,235

0

0

0

Supplemental disclosure of cash flow information:
Obtaining a right-of-use asset in exchange for a lease liability

0

900

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

957

1,182

1,412

1,640

1,875

2,092

2,245

2,283

2,512

2,279

2,111

2,000

1,696

1,762

1,986

2,025

1,911

0

0

0